Whitehawk Therapeutics (WHWK) Competitors $1.72 -0.08 (-4.44%) As of 08/7/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock WHWK vs. NMRA, RCKT, RNAC, INBX, AURA, CADL, NBTX, AVIR, OCGN, and NGNEShould you be buying Whitehawk Therapeutics stock or one of its competitors? The main competitors of Whitehawk Therapeutics include Neumora Therapeutics (NMRA), Rocket Pharmaceuticals (RCKT), Cartesian Therapeutics (RNAC), Inhibrx Biosciences (INBX), Aura Biosciences (AURA), Candel Therapeutics (CADL), Nanobiotix (NBTX), Atea Pharmaceuticals (AVIR), Ocugen (OCGN), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. Whitehawk Therapeutics vs. Its Competitors Neumora Therapeutics Rocket Pharmaceuticals Cartesian Therapeutics Inhibrx Biosciences Aura Biosciences Candel Therapeutics Nanobiotix Atea Pharmaceuticals Ocugen Neurogene Neumora Therapeutics (NASDAQ:NMRA) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings. Which has stronger earnings & valuation, NMRA or WHWK? Whitehawk Therapeutics has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$243.79M-$1.57-1.05Whitehawk Therapeutics$27.78M2.92-$63.69M$0.1610.75 Do analysts prefer NMRA or WHWK? Neumora Therapeutics currently has a consensus target price of $7.14, indicating a potential upside of 332.90%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Neumora Therapeutics is more favorable than Whitehawk Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22Whitehawk Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NMRA or WHWK more profitable? Whitehawk Therapeutics has a net margin of 99.42% compared to Neumora Therapeutics' net margin of 0.00%. Whitehawk Therapeutics' return on equity of -56.73% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -90.44% -81.65% Whitehawk Therapeutics 99.42%-56.73%-48.68% Do insiders and institutionals believe in NMRA or WHWK? 47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 26.8% of Neumora Therapeutics shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, NMRA or WHWK? Neumora Therapeutics has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Does the media refer more to NMRA or WHWK? In the previous week, Neumora Therapeutics had 6 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 8 mentions for Neumora Therapeutics and 2 mentions for Whitehawk Therapeutics. Neumora Therapeutics' average media sentiment score of 0.46 beat Whitehawk Therapeutics' score of -1.50 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Whitehawk Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Negative SummaryWhitehawk Therapeutics beats Neumora Therapeutics on 9 of the 15 factors compared between the two stocks. Get Whitehawk Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WHWK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WHWK vs. The Competition Export to ExcelMetricWhitehawk TherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$84.80M$785.27M$2.53B$9.57BDividend YieldN/A4.84%2.57%4.18%P/E Ratio10.751.2922.2325.14Price / Sales2.9225.4387.4197.17Price / CashN/A19.5626.8658.58Price / Book0.816.5737.255.59Net Income-$63.69M-$3.92M$28.61M$265.48M7 Day Performance-1.15%-2.83%1.46%1.22%1 Month Performance-13.57%-0.30%0.88%0.39%1 Year PerformanceN/A23.98%30.09%23.47% Whitehawk Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WHWKWhitehawk TherapeuticsN/A$1.72-4.4%N/AN/A$84.80M$27.78M10.7540News CoverageNegative NewsEarnings ReportGap DownNMRANeumora Therapeutics2.9742 of 5 stars$2.08-5.0%$7.14+243.4%-86.0%$336.44MN/A-1.29108News CoverageGap UpRCKTRocket Pharmaceuticals4.8393 of 5 stars$3.14+4.3%$17.87+469.0%-83.7%$335.32MN/A-1.19240Trending NewsEarnings ReportRNACCartesian Therapeutics2.1165 of 5 stars$12.85-4.1%$40.00+211.3%-25.8%$333.46M$38.91M-0.2464News CoveragePositive NewsINBXInhibrx Biosciences1.364 of 5 stars$22.99-5.2%N/A+86.2%$332.90M$200K0.20166Upcoming EarningsGap UpAURAAura Biosciences1.9621 of 5 stars$6.59-2.9%$22.00+233.8%-20.0%$331.28MN/A-3.4750News CoverageUpcoming EarningsCADLCandel Therapeutics2.5734 of 5 stars$6.57flat$22.00+234.9%+16.3%$329.16M$120K-4.9060Upcoming EarningsNBTXNanobiotix0.8242 of 5 stars$6.69-3.8%$8.00+19.7%+53.6%$315.06M$39.18M0.00100Gap UpAVIRAtea Pharmaceuticals2.2552 of 5 stars$3.67-3.4%$6.00+63.5%+5.8%$314.08MN/A-2.2270News CoverageEarnings ReportOCGNOcugen1.7731 of 5 stars$1.07+3.9%$6.00+460.7%-15.3%$312.47M$4.05M-5.6380Earnings ReportAnalyst RevisionNGNENeurogene2.9963 of 5 stars$21.87+4.1%$46.17+111.1%-40.9%$311.91M$925K-5.0390News Coverage Related Companies and Tools Related Companies NMRA Competitors RCKT Competitors RNAC Competitors INBX Competitors AURA Competitors CADL Competitors NBTX Competitors AVIR Competitors OCGN Competitors NGNE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WHWK) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Whitehawk Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Whitehawk Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
